Viking Therapeutics(US:VKTX) ZACKS·2025-10-17 22:45Company Performance - Viking Therapeutics, Inc. (VKTX) shares decreased by 3.44% to $33.54, underperforming the S&P 500's daily gain of 0.53% [1] - Over the last month, the company's shares increased by 33.37%, significantly outperforming the Medical sector's gain of 2.87% and the S&P 500's gain of 0.71% [1] Earnings Projections - The upcoming earnings report for Viking Therapeutics is scheduled for October 22, 2025, with projected earnings per share (EPS) of -$0.7, indicating a 218.18% decrease from the same quarter last year [2] - For the annual period, Zacks Consensus Estimates predict an EPS of -$2.45 and revenue of $0 million, reflecting shifts of -142.57% and 0% respectively from the previous year [3] Analyst Estimates and Rankings - Recent adjustments to analyst estimates for Viking Therapeutics are crucial as they reflect near-term business trends, with positive changes indicating a favorable outlook on business health and profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Viking Therapeutics at 4 (Sell), with a consensus EPS projection having moved 1.06% higher in the past 30 days [5] Industry Context - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, holds a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of specific industry groups, with research indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]